Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional verapamil versus triamcinolone for keloids and hypertrophic scars
ACTRN12625000568415Phase 4Recruiting
- Sponsor
- Noor ul Huda working as resident in khyber teaching hospital Peshawar.
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of verapamil and triamcinolone in keloid and Hypertrophic Scar (HS) (2 arms), sponsored by Noor ul Huda working as resident in khyber teaching hospital Peshawar. Primary endpoints: Efficacy based on Vancouver Scar Scale and Mean change in scar height. Started Dec 2024; status: recruiting.
02
Drugs
verapamiltriamcinolone
03
Conditions
keloidHypertrophic Scar (HS)
Beyond the preview
Go deeper on ACTRN12625000568415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000568415.